CSPC Pharmaceutical Group (SEHK:1093) Could Be 115% Below Fair Value Following Drug Approval

CSPC Pharmaceutical Group (SEHK:1093) has secured marketing approval in China for its once-monthly Paliperidone Palmitate Injection for schizophrenia, a development that broadens its psychiatric and neurological drug portfolio.

See our latest analysis for CSPC Pharmaceutical Group.

The marketing approval for CSPC Pharmaceutical Group’s Paliperidone Palmitate Injection comes as momentum in the stock has recently strengthened. The 30 day share price return is 28.57%, following earlier 90 day weakness when the share price fell 4.79%. The 3 year total shareholder return of 47.46% contrasts with a modest 2.85% total shareholder return over the past year.

If this kind of product news has your attention, it can be a good moment to widen your watchlist using a healthcare focused screener such as 129 healthcare AI stocks

CSPC Pharmaceutical Group’s share price has already jumped on the Paliperidone news, so the question now is whether that move already reflects the value on offer or whether waiting for a cooler entry makes more sense.

Preferred P/E of 25.9x: Is it justified for CSPC Pharmaceutical Group?

CSPC Pharmaceutical Group is trading on a P/E of 25.9x, which sits above several reference points, so the current share price already bakes in a relatively full earnings valuation compared to peers.

The P/E ratio compares what you pay today for each unit of current earnings. For a pharmaceutical company like CSPC Pharmaceutical Group, it reflects how much investors are willing to pay for its existing profit stream and the earnings growth that might come from its drug portfolio and pipeline.

Here, the stock trades on 25.9x earnings while the estimated fair P/E from the SWS fair ratio model is 19.7x. That is a clear premium to the level the market could move towards if sentiment or expectations moderate. It is also higher than the Hong Kong Pharmaceuticals industry average P/E of 14.1x and slightly above the peer average of 25.5x, which suggests investors are paying more for CSPC Pharmaceutical Group’s earnings than for the typical sector or peer company.

Explore the SWS fair ratio for CSPC Pharmaceutical Group

Result: Price-to-earnings of 25.9x (OVERVALUED)

However, CSPC Pharmaceutical Group’s higher P/E and recent 30 day share price jump of 28.57% leave less room for disappointment if sentiment or earnings expectations soften.

Find out about the key risks to this CSPC Pharmaceutical Group narrative.

Another View on CSPC Pharmaceutical Group’s Valuation

While CSPC Pharmaceutical Group looks expensive on a 25.9x P/E relative to its fair ratio of 19.7x, the SWS DCF model points the other way, with an estimated future cash flow value of HK$18.40 versus the current HK$8.55 share price. This implies the stock is undervalued on that basis.

This kind of gap between earnings based and cash flow based views raises an important question for you as an investor: which signal should carry more weight when sentiment around CSPC Pharmaceutical Group shifts next?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CSPC Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 247 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

With sentiment around CSPC Pharmaceutical Group looking mixed, it makes sense to move quickly, review the full picture, and weigh both sides using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond CSPC Pharmaceutical Group?

If CSPC Pharmaceutical Group has you thinking more broadly about opportunities, do not stop here. Use targeted screens to uncover stocks that better match your approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com